Original Clinical ScienceThe impact of pre-transplant allosensitization on outcomes after lung transplantation
Section snippets
Study design
We conducted a retrospective cohort study including all patients listed for lung transplantation at our program between January 1, 2006, and December 31, 2011. During this period, 368 patients were listed for transplantation; 3 subsequently underwent transplant at another institution and were excluded. Of the remaining 365 patients, 304 underwent transplant at our center before December 31, 2012, and comprise this cohort. The remaining 61 patients died while on the waitlist, were removed from
Baseline characteristics and histocompatibility
Follow-up was complete through December 31, 2013, and the study included 974 patient-years of follow-up with a mean follow-up of 3.2 ± 1.9 years. Among the 304 recipients, 108 (35.5%) were allosensitized before transplantation, and 196 (64.5%) were not allosensitized (Table 1). Overall, there was no significant difference in baseline characteristics between recipients who were allosensitized and recipients who were not allosensitized (Table 1). Among the 108 allosensitized recipients, 29 (27%)
Discussion
In this study, we examined the impact of pre-transplant allosensitization on post-transplant outcomes in the era of solid-phase multiplex HLA antibody detection assays and virtual crossmatching. Our analysis did not reveal any association between pre-transplant allosensitization and adverse outcomes after lung transplantation. Specifically, we found no association between pre-transplant allosensitization and the development of ACR, LB, DSA, CLAD, or graft failure. Moreover, we found no
Disclosure statement
This work was supported in part the National Institutes of Health (Grant No. HL056643 to T.M. and R.R.H. and Grant No. HL105412 to R.D.Y., T.M., and R.R.H.).
None of the authors has a financial relationship with a commercial entity that has an interest in the subject of the presented manuscript or other conflicts of interest to disclose.
References (24)
- et al.
The Registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report—2014; focus theme: retransplatnation
J Heart Lung Transplant
(2014) - et al.
De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation
J Heart Lung Transplant
(2014) - et al.
HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction
Am J Transplant
(2005) - et al.
HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection
J Heart Lung Transplant
(2004) - et al.
Acute antibody-mediated rejection after lung transplantation
J Heart Lung Transplant
(2013) - et al.
Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients
Chest
(2013) - et al.
Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients
Ann Thorac Surg
(2000) - et al.
Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study
J Heart Lung Transplant
(2005) - et al.
Pretransplant panel reactive antibodies in human lung transplantation: an analysis of over 10,000 patients
Ann Thorac Surg
(2008) - et al.
Allosensitization increases the risk of death on the lung transplant waiting list
J Heart Lung Transplant
(2014)
Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria
J Heart Lung Transplant
A new classification system for chronic lung allograft dysfunction
J Heart Lung Transplant
Cited by (33)
Lung transplantation despite preformed donor-specific antihuman leukocyte antigen antibodies: a 9-year single-center experience
2023, American Journal of TransplantationAntibody-Mediated Rejection: Diagnosis and Treatment
2023, Clinics in Chest MedicinePoint-Counterpoint: Desensitization to improve the likelihood of lung transplantation
2023, Human ImmunologyThe allograft injury marker CXCL9 determines prognosis of anti-HLA antibodies after lung transplantation
2022, American Journal of TransplantationConsensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation
2021, Journal of Heart and Lung TransplantationCitation Excerpt :Human Leucocyte Antigen (HLA) Antibodies: Elevated HLA specific antibodies detected in peripheral blood may make finding a compatible donor difficult and may predict poor outcomes.59-61 However, some centers describe successful lung transplantation despite positive cross match.62,63 Cut-off levels for organ acceptance and the optimal methods for detection of functional donor specific antibodies have not been determined.
Lung Transplantation for Chronic Obstructive Pulmonary Disease
2021, Encyclopedia of Respiratory Medicine, Second Edition